Blue Earth highlights new Axumin research

By staff writers

September 27, 2021 -- Bracco molecular imaging subsidiary Blue Earth Diagnostics is directing attention to new research that found PET/CT imaging with its Axumin (fluciclovine F-18) PET radiopharmaceutical had a significant impact on management of patients with recurrent prostate cancer.

In a secondary analysis of the LOCATE and FALCON prospective clinical trials, researchers from the Washington University School of Medicine reported that Axumin PET/CT detected lesions in 85 (58%) of the 146 patients who had received a prescan plan for androgen deprivation therapy, according to Blue Earth. Of the 146, 93 (64%) had a change in their management plan following the exam.

Androgen deprivation therapy was avoided or delayed in 55 (59%) of the 93 patients whose management plan had changed. In addition, only 15 (25%) of the 60 patients originally planned for androgen deprivation therapy monotherapy were still due to receive that treatment plan after Axumin PET/CT imaging, according to Blue Earth.

The results were presented on September 23 at the Global Summit on Precision Diagnosis and Treatment of Prostate Cancer.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking